Pharmacokinetics and metabolism of the nitrogen mustard bioreductive drug 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide (SN 23862) and the corresponding aziridine (CB 1954) in KHT tumour-bearing mice

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s002800000165PMID 11127940
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro degradation of l-phenylalanine mustard (l-PAM)

  2004cited by this paper
• Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy

  2004cited by this paper
• High-performance liquid chromatographic method for sensitive determination of the alkylating agent CB1954 in human plasma.

  1999cited by this paper
• Bioreductive therapies: an overview of drugs and their mechanisms of action.

  1998cited by this paper
• Bioreductive drugs into the next millennium.

  1998cited by this paper
• Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954

  1998cited by this paper
• Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.

  1997cited by this paper
• Ifosfamide Metabolite Chloroacetaldehyde Causes Renal Dysfunction in vivo

  1997cited by this paper
• Nitro reduction as an electronic switch for bioreductive drug activation.

  1997cited by this paper
• Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy.

  1996cited by this paper
• Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.

  1996cited by this paper
• Oxidative metabolism of 1-(2-chloroethyl)-3-alkyl-3- (methylcarbamoyl)triazenes: formation of chloroacetaldehyde and relevance to biological activity.

  1996cited by this paper
• Recent developments in the design of bioreductive drugs.

  1996cited by this paper
• Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase.

  1995cited by this paper
• Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.

  1995cited by this paper
• Hypoxia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.

  1994cited by this paper
• Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs)

  1993cited by this paper
• Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione.

  1993cited by this paper
• The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)

  1993cited by this paper
• Cytochrome P-450-mediated N-dechloroethylation of cyclophosphamide and ifosfamide in the rat.

  1992cited by this paper
• Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells.

  1992cited by this paper
• The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase.

  1992cited by this paper
• Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species.

  1991cited by this paper
• New colorimetric cytotoxicity assay for anticancer-drug screening.

  1990cited by this paper
• Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines.

  1990cited by this paper
• A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.

  1988cited by this paper
• The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2).

  1988cited by this paper
• Metabolism and excretion of dinitrobenzenes by male Fischer-344 rats.

  1987cited by this paper
• Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells.

  1986cited by this paper
• Hydrolysis of ester- and amide-type drugs by the purified isoenzymes of nonspecific carboxylesterase from rat liver.

  1984cited by this paper
• Pharmacology of the mixed-function radio- and chemosensitizers CB 1954 and RSU 1069.

  1984cited by this paper
• Metabolism of nitromide in the rat. II. Sites of nitro-reduction.

  1980cited by this paper
• The metabolism of the anti-tumour agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954).

  1976cited by this paper
• Metabolism of aniline mustard (N,N-di-(2-chloroethyl)aniline).

  1973cited by this paper
• Toxicity profile of chloroacetaldehyde.

  1972cited by this paper
• 2,4-dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of the growth of the Walker carcinoma 256.

  1969cited by this paper

• Enzyme/Prodrug Systems for Cancer Gene Therapy

  2016cites this paper
• Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

  2015cites this paper
• Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.

  2015cites this paper
• Discovery and Optimisation of Bacterial Nitroreductases for Use in Anti-Cancer Gene Therapy

  2011cites this paper
• Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice, Rats, Dogs, and Humans

  2010cites this paper
• ROLES OF BIOTRANSFORMATION IN THE ANTITUMOUR ACTIVITY AND TOXICOLOGY OF THE HYPOXIA-ACTIVATED PRE- PRODRUG PR-104

  2010cites this paper
• Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice, Rats, Dogs and Humans

  2009cites this paper
• Metabolism and Excretion of the Novel Bioreductive Prodrug PR-104 in Mice, Rats, Dogs and Humans

  2009cites this paper
• Influence of Mustard Group Structure on Pathways of in Vitro Metabolism of Anticancer N-(2-Hydroxyethyl)-3,5-dinitrobenzamide 2-Mustard Prodrugss⃞

  2008cites this paper
• Synthesis of 3H‐ and 2H4‐labelled versions of the hypoxia‐activated pre‐prodrug 2‐[(2‐bromoethyl)‐2,4‐dinitro‐6‐ [[[2‐(phosphonooxy)ethyl]amino]carbonyl]anilino]ethyl methanesulfonate (PR‐104)

  2007cites this paper
• Hepatic nitroreduction, toxicity and toxicokinetics of the anti-tumour prodrug CB 1954 in mouse and rat.

  2007cites this paper
• The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411NTR

  2007cites this paper
• Metabolic enzyme considerations in cancer therapy.

  2007cites this paper
• Aerobic 2- and 4-nitroreduction of CB 1954 by human liver.

  2005cites this paper
• 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT

  2004cites this paper
• Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy)

  2003cites this paper
• Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.

  2003cites this paper
• Nitroreductase-based GDEPT.

  2002cites this paper
• Synthesis of 1H-2,3-dihydropyrrolizine derivatives as precursors of bifunctional alkylating agents

  2002cites this paper
• Challenges of cancer drug design: a drug metabolism perspective.

  2001cites this paper